Related Experiment Video
Updated: Jul 16, 2026
Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
Published on: September 14, 2017
Umbilical cord blood stem cells: implications for cardiovascular regenerative medicine
Jonathan L Goldberg1, Mary J Laughlin, Vincent J Pompili
1Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, OH 44106-7284, USA.
Insights
Umbilical cord blood stem cells show promise for treating vascular disease, offering a safe and readily available therapeutic option. Further research is needed to understand their precise mechanism of action in promoting healing.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Background:
- Cardiovascular disease (CVD) management has improved, but complex cases require novel therapies.
- Cellular therapy is being explored to enhance compensatory mechanisms and prevent disease progression.
- Umbilical cord blood (UCB) is a potential source for hematopoietic stem cells (HSC) for therapeutic applications.
Purpose of the Study:
- To investigate the potential of UCB-derived HSC in managing complex vascular diseases.
- To evaluate the efficacy and safety of UCB HSC therapy in preclinical and clinical settings.
- To explore the underlying mechanisms of UCB HSC in promoting vascular repair.
Main Methods:
- Review of in vitro and in vivo studies on UCB HSC therapy.
- Analysis of UCB collection, availability, and immunological properties.
- Assessment of stem cell function in patients with chronic diseases.
Main Results:
- UCB HSC offer advantages including no donor risk, immediate availability, and lower immune reactivity.
- Studies indicate UCB HSC show benefits in both acute and chronic vascular ischemia.
- Observed efficacy in vascular repair with no apparent safety concerns.
Conclusions:
- UCB HSC represent a promising cell source for treating vascular ischemia.
- The therapeutic mechanism of UCB HSC in vascular repair remains to be elucidated.
- Further investigation is warranted to fully understand and optimize UCB HSC-based therapies for cardiovascular disease.
Abstract:
The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:17Stem Cell Culture
01:19Multipotency of Hematopoietic Stem Cells
01:22iPS Cell Differentiation